Patents by Inventor Harald Engelhardt

Harald Engelhardt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200377476
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Dietrich BOESE, Georg DAHMANN, Harald ENGELHARDT, Mark PETRONCZKI, Dirk SCHARN
  • Publication number: 20200291020
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R5, A and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 1, 2018
    Publication date: September 17, 2020
    Inventors: Harald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco HOFMANN, Marc KERENYI, Dirk SCHARN
  • Publication number: 20190290637
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R2 to R5, A, X and q have the meanings given in the claims and specification, their use as inhibitors of CDK8/19, pharmaceutical compositions which contain compounds of this kind and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 26, 2019
    Inventors: Harald ENGELHARDT, Heribert ARNHOF, Sebastian CAROTTA, Marco Hans HOFMANN, Marc KERENYI, Dirk SCHARN
  • Publication number: 20190240219
    Abstract: Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: April 19, 2019
    Publication date: August 8, 2019
    Inventors: Harald ENGELHARDT, Davide GIANNI, Christian SMETHURST
  • Patent number: 10328074
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 9428513
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Patent number: 9428515
    Abstract: The present invention encompasses compounds of the general formula I wherein the groups A, R1 to R2 and X have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: August 30, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventor: Harald Engelhardt
  • Patent number: 9422290
    Abstract: Disclosed are compounds of general formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: August 23, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Dirk Kessler, Ulrich Reiser, Christian Smethurst, Andreas Steffen
  • Publication number: 20160129001
    Abstract: Method for treating AML and MM by administration of a compound of the formula (I) wherein the groups R1 to R3 have the meanings given in the specification.
    Type: Application
    Filed: January 14, 2016
    Publication date: May 12, 2016
    Inventors: Harald ENGELHARDT, Davide GIANNI, Christian SMETHURST
  • Patent number: 9296748
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: March 29, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Laetitia Martin, Christian Smethurst
  • Patent number: 9266891
    Abstract: Disclosed are compounds of the formula (I) wherein the groups R1 to R3 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: February 23, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Christian Smethurst
  • Patent number: 9199988
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: December 1, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Christian Smethurst, Harald Engelhardt, Davide Gianni, Ulrich Reiser
  • Publication number: 20150322073
    Abstract: The present invention encompasses compounds of the general formula I wherein the groups A, R1 to R2 and X have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: May 7, 2015
    Publication date: November 12, 2015
    Inventor: Harald ENGELHARDT
  • Publication number: 20150246919
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: May 18, 2015
    Publication date: September 3, 2015
    Inventors: Harald ENGELHARDT, Laetitia MARTIN, Christian SMETHURST
  • Patent number: 9102684
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: August 11, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Davide Gianni, Andreas Mantoulidis, Christian Smethurst
  • Publication number: 20150133447
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3, X3 to X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: November 4, 2014
    Publication date: May 14, 2015
    Inventor: Harald ENGELHARDT
  • Publication number: 20150051208
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R3 and X1 through X6 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: August 11, 2014
    Publication date: February 19, 2015
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald ENGELHARDT, Laetitia MARTIN, Christian SMETHURST
  • Patent number: 8895581
    Abstract: The present invention encompasses compounds of general formula (1), wherein the groups R1 to R7, Qa, Qb, L, n and m are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, pharmaceutical preparations containing such compounds and their use as medicaments.
    Type: Grant
    Filed: May 17, 2011
    Date of Patent: November 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Darryl McConnell, Harald Engelhardt, Christiane Kofink
  • Publication number: 20140296230
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4 and A1 to A5 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Christian SMETHURST, Harald ENGELHARDT, Davide GIANNI, Ulrich REISER
  • Publication number: 20140296229
    Abstract: The present invention encompasses compounds of general formula (I) wherein the groups R1 to R4, A1 and A2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation pharmaceutical preparations containing such compounds and their uses as a medicament.
    Type: Application
    Filed: March 26, 2014
    Publication date: October 2, 2014
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Harald ENGELHARDT, Davide GIANNI, Andreas MANTOULIDIS, Christian SMETHURST